JP2015520752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520752A5 JP2015520752A5 JP2015511730A JP2015511730A JP2015520752A5 JP 2015520752 A5 JP2015520752 A5 JP 2015520752A5 JP 2015511730 A JP2015511730 A JP 2015511730A JP 2015511730 A JP2015511730 A JP 2015511730A JP 2015520752 A5 JP2015520752 A5 JP 2015520752A5
- Authority
- JP
- Japan
- Prior art keywords
- carboxamide
- phenyl
- pyridazin
- azetidine
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000304 alkynyl group Chemical group 0.000 claims description 95
- 125000000217 alkyl group Chemical group 0.000 claims description 92
- 125000003342 alkenyl group Chemical group 0.000 claims description 90
- 125000000623 heterocyclic group Chemical group 0.000 claims description 72
- 125000003118 aryl group Chemical group 0.000 claims description 70
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 70
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 70
- 229910052739 hydrogen Inorganic materials 0.000 claims description 57
- 125000001424 substituent group Chemical group 0.000 claims description 57
- OTXBWGUYZNKPMG-UHFFFAOYSA-N isofulminic acid Chemical compound O[N+]#[C-] OTXBWGUYZNKPMG-UHFFFAOYSA-N 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 12
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims description 10
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 claims description 5
- 101100240517 Caenorhabditis elegans nhr-11 gene Proteins 0.000 claims description 5
- 101100240518 Caenorhabditis elegans nhr-12 gene Proteins 0.000 claims description 5
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- -1 4-{[1- (tetrahydro-2H-pyran-4-ylacetyl) piperidin-4-yl] oxy} phenyl Chemical group 0.000 claims 648
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 416
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 270
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 118
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 55
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 37
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 claims 17
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 13
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 10
- 125000006334 2,4-difluoro benzoyl group Chemical group [H]C1=C([H])C(C(*)=O)=C(F)C([H])=C1F 0.000 claims 7
- VALZSZJVEFACEZ-UHFFFAOYSA-N azetidine-3-carboxamide Chemical compound NC(=O)C1CNC1 VALZSZJVEFACEZ-UHFFFAOYSA-N 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 208000030507 AIDS Diseases 0.000 claims 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 150000003857 carboxamides Chemical class 0.000 claims 6
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 5
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 4
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 claims 4
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010006895 Cachexia Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 206010043189 Telangiectasia Diseases 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 210000003679 cervix uteri Anatomy 0.000 claims 3
- 210000001072 colon Anatomy 0.000 claims 3
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 210000001672 ovary Anatomy 0.000 claims 3
- 210000000496 pancreas Anatomy 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 210000003491 skin Anatomy 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 208000009056 telangiectasis Diseases 0.000 claims 3
- DAUYIKBTMNZABP-UHFFFAOYSA-N thiophene-3-carboxamide Chemical compound NC(=O)C=1C=CSC=1 DAUYIKBTMNZABP-UHFFFAOYSA-N 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 230000017423 tissue regeneration Effects 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 210000003932 urinary bladder Anatomy 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- AFNCBWNNOVTDGK-UHFFFAOYSA-N 1-methyl-5-[4-[(1-pyridazin-3-ylazetidine-3-carbonyl)amino]phenyl]pyrazole-3-carboxylic acid Chemical compound CN1N=C(C(O)=O)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 AFNCBWNNOVTDGK-UHFFFAOYSA-N 0.000 claims 2
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 2
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 claims 2
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims 2
- 125000000070 5-oxo-L-proline group Chemical group [H]N1[C@@](C(=O)[*])([H])C([H])([H])C([H])([H])C1=O 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 claims 2
- KGEXKCMGYQQMLW-UHFFFAOYSA-N n-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1NCC1C(=O)NC1=CC=CN=N1 KGEXKCMGYQQMLW-UHFFFAOYSA-N 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 230000037380 skin damage Effects 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- CFFQGPNPYLDEPC-NRFANRHFSA-N (3s)-1-(2-methylpyridin-3-yl)-n-[4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl]pyrrolidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CCC(F)(F)F)CC1 CFFQGPNPYLDEPC-NRFANRHFSA-N 0.000 claims 1
- LGKXFNXCSXWDCA-VWLOTQADSA-N (3s)-n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)CC1 LGKXFNXCSXWDCA-VWLOTQADSA-N 0.000 claims 1
- DPPPEFNITFVTDY-DEOSSOPVSA-N (3s)-n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound CC1=CC=NN=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)CC1 DPPPEFNITFVTDY-DEOSSOPVSA-N 0.000 claims 1
- HRXSPZLJDLALOP-DEOSSOPVSA-N (3s)-n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)CC1 HRXSPZLJDLALOP-DEOSSOPVSA-N 0.000 claims 1
- SZXCWTSHMDPRJZ-NRFANRHFSA-N (3s)-n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound CC1=CC=NN=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)C)CC1 SZXCWTSHMDPRJZ-NRFANRHFSA-N 0.000 claims 1
- ZLYQUUMVCSOWTG-NRFANRHFSA-N (3s)-n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)C)CC1 ZLYQUUMVCSOWTG-NRFANRHFSA-N 0.000 claims 1
- WALDIRUCVXEFFT-DEOSSOPVSA-N (3s)-n-[4-[1-(2-cyclopentylacetyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1C=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CC1CCCC1 WALDIRUCVXEFFT-DEOSSOPVSA-N 0.000 claims 1
- PQFYGXUEGPMBBB-QHCPKHFHSA-N (3s)-n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)CC1 PQFYGXUEGPMBBB-QHCPKHFHSA-N 0.000 claims 1
- RMVLRRDBYRXBFZ-QFIPXVFZSA-N (3s)-n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)CC1 RMVLRRDBYRXBFZ-QFIPXVFZSA-N 0.000 claims 1
- YJHSZTJRQKVYKC-UHFFFAOYSA-N 1-(2-cyanopyridin-3-yl)-n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(O)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C#N)C1 YJHSZTJRQKVYKC-UHFFFAOYSA-N 0.000 claims 1
- KSBDOXBQIVLQCX-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-(1-pentanoylpiperidin-4-yl)phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 KSBDOXBQIVLQCX-UHFFFAOYSA-N 0.000 claims 1
- SEDBIAKWSHVRAG-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-(1-propanoylpiperidin-4-yl)phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 SEDBIAKWSHVRAG-UHFFFAOYSA-N 0.000 claims 1
- LAGSTDKHZWEKEI-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CC(F)(F)F)C1 LAGSTDKHZWEKEI-UHFFFAOYSA-N 0.000 claims 1
- FZCQQQLSNRSDDF-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CCC(F)(F)F)C1 FZCQQQLSNRSDDF-UHFFFAOYSA-N 0.000 claims 1
- DQYSOZAEYBERTP-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC(=CC=2)C(F)(F)F)C1 DQYSOZAEYBERTP-UHFFFAOYSA-N 0.000 claims 1
- IITCHUJZTMPPHI-UHFFFAOYSA-N 1-(4-cyanopyridin-3-yl)-n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(O)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=CC=NC=2)C#N)C1 IITCHUJZTMPPHI-UHFFFAOYSA-N 0.000 claims 1
- IXXDXUKXEALHCM-UHFFFAOYSA-N 1-(6-fluoropyridazin-3-yl)-n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC(F)=CC=2)C1 IXXDXUKXEALHCM-UHFFFAOYSA-N 0.000 claims 1
- 125000004486 1-methylpiperidin-3-yl group Chemical group CN1CC(CCC1)* 0.000 claims 1
- BEGIUDFULSWUTQ-HNNXBMFYSA-N 2-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=NC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)S1 BEGIUDFULSWUTQ-HNNXBMFYSA-N 0.000 claims 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000005916 2-methylpentyl group Chemical group 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- DSNABZXHIMPTJG-MRXNPFEDSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3r)-1-pyridazin-4-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@H]2CN(CC2)C=2C=NN=CC=2)S1 DSNABZXHIMPTJG-MRXNPFEDSA-N 0.000 claims 1
- DSNABZXHIMPTJG-INIZCTEOSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3s)-1-pyridazin-4-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2C=NN=CC=2)S1 DSNABZXHIMPTJG-INIZCTEOSA-N 0.000 claims 1
- 208000028990 Skin injury Diseases 0.000 claims 1
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 1
- AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 claims 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- XQYJYFKSVFZAMI-UHFFFAOYSA-N n-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 XQYJYFKSVFZAMI-UHFFFAOYSA-N 0.000 claims 1
- LPAQODLQHMVXLX-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-cyanopyridin-3-yl)azetidine-3-carboxamide Chemical compound C1N(C=2C(=NC=CC=2)C#N)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC=C1 LPAQODLQHMVXLX-UHFFFAOYSA-N 0.000 claims 1
- OJUAUJFCYYPGLV-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-fluoro-6-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound FC1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 OJUAUJFCYYPGLV-UHFFFAOYSA-N 0.000 claims 1
- AEYPUVFOVVWCMP-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 AEYPUVFOVVWCMP-UHFFFAOYSA-N 0.000 claims 1
- WGTLDTUCKQYSOT-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(3-methylpyridazin-4-yl)azetidine-3-carboxamide Chemical compound CC1=NN=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 WGTLDTUCKQYSOT-UHFFFAOYSA-N 0.000 claims 1
- ZHFYXBULYSSPEG-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-cyanopyridin-3-yl)azetidine-3-carboxamide Chemical compound C1N(C=2C(=CC=NC=2)C#N)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC=C1 ZHFYXBULYSSPEG-UHFFFAOYSA-N 0.000 claims 1
- FHUJRSVESRDLDU-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound CC1=CC=NN=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 FHUJRSVESRDLDU-UHFFFAOYSA-N 0.000 claims 1
- CUTZPQDHZGWHMS-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-cyanopyridin-3-yl)azetidine-3-carboxamide Chemical compound C1N(C=2C=C(C=NC=2)C#N)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC=C1 CUTZPQDHZGWHMS-UHFFFAOYSA-N 0.000 claims 1
- RYTOFSKAMVCQRI-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-fluoropyridin-3-yl)azetidine-3-carboxamide Chemical compound FC1=CN=CC(N2CC(C2)C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)=C1 RYTOFSKAMVCQRI-UHFFFAOYSA-N 0.000 claims 1
- AKMQGPDGYFVBNR-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=CN=CC(N2CC(C2)C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)=C1 AKMQGPDGYFVBNR-UHFFFAOYSA-N 0.000 claims 1
- QDAUTOGWKLGJOZ-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-4-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=CC(F)=NC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 QDAUTOGWKLGJOZ-UHFFFAOYSA-N 0.000 claims 1
- ANBICJLAOHZPHN-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-5-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound N1=C(F)C(C)=CC(N2CC(C2)C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)=C1 ANBICJLAOHZPHN-UHFFFAOYSA-N 0.000 claims 1
- UIIWQNMWUGKRQO-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(F)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 UIIWQNMWUGKRQO-UHFFFAOYSA-N 0.000 claims 1
- ALSZCAJBHOIQPC-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 ALSZCAJBHOIQPC-UHFFFAOYSA-N 0.000 claims 1
- JPHIUQBTGPZROV-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 JPHIUQBTGPZROV-UHFFFAOYSA-N 0.000 claims 1
- AAFKUGOODNIZRH-UHFFFAOYSA-N n-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 AAFKUGOODNIZRH-UHFFFAOYSA-N 0.000 claims 1
- JWPLXQJKYCOOTB-UHFFFAOYSA-N n-[4-(phenylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NC1=CC=CC=C1 JWPLXQJKYCOOTB-UHFFFAOYSA-N 0.000 claims 1
- YOZLCPKRAGNSCD-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 YOZLCPKRAGNSCD-UHFFFAOYSA-N 0.000 claims 1
- SJEKTXYPKWKYSF-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)C)C1 SJEKTXYPKWKYSF-UHFFFAOYSA-N 0.000 claims 1
- MNAPTKLAMZJYCE-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC(F)=CC=2)C1 MNAPTKLAMZJYCE-UHFFFAOYSA-N 0.000 claims 1
- WVVPZDOEXIEHRW-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)C)C1 WVVPZDOEXIEHRW-UHFFFAOYSA-N 0.000 claims 1
- QNUPXEVKEHZIGA-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropyl)pyrazol-4-yl]phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2=CN(CC(C)(C)C)N=C2)C1 QNUPXEVKEHZIGA-UHFFFAOYSA-N 0.000 claims 1
- QOMIPYCQXFBFNM-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropyl)pyrazol-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=NN(CC(C)(C)C)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 QOMIPYCQXFBFNM-UHFFFAOYSA-N 0.000 claims 1
- ZCODHRWWMZHIDU-UHFFFAOYSA-N n-[4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 ZCODHRWWMZHIDU-UHFFFAOYSA-N 0.000 claims 1
- LXMDESIWPXPBER-UHFFFAOYSA-N n-[4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)Cl)C1 LXMDESIWPXPBER-UHFFFAOYSA-N 0.000 claims 1
- DACQESBPRDQXEW-UHFFFAOYSA-N n-[4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(CC)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC(F)=CC=2)C1 DACQESBPRDQXEW-UHFFFAOYSA-N 0.000 claims 1
- QFAMAWMJJYMGJV-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)C1 QFAMAWMJJYMGJV-UHFFFAOYSA-N 0.000 claims 1
- FQJKMPGDXXVFOQ-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(3-methylpyridazin-4-yl)azetidine-3-carboxamide Chemical compound CC1=NN=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)C1 FQJKMPGDXXVFOQ-UHFFFAOYSA-N 0.000 claims 1
- JCJNNKHGEGGRDE-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(F)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)C1 JCJNNKHGEGGRDE-UHFFFAOYSA-N 0.000 claims 1
- VUZFFXIHMDVURC-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)C1 VUZFFXIHMDVURC-UHFFFAOYSA-N 0.000 claims 1
- ONWURVDIDPOPEM-UHFFFAOYSA-N n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1-(2-methoxypyridin-3-yl)azetidine-3-carboxamide Chemical compound COC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)O)C1 ONWURVDIDPOPEM-UHFFFAOYSA-N 0.000 claims 1
- TXYCVDYUTCHHNH-UHFFFAOYSA-N n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)O)C1 TXYCVDYUTCHHNH-UHFFFAOYSA-N 0.000 claims 1
- KYOTZCGBZNGMGM-UHFFFAOYSA-N n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1-(4-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=CC=NC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)O)C1 KYOTZCGBZNGMGM-UHFFFAOYSA-N 0.000 claims 1
- CGMMOCAINOCYJN-UHFFFAOYSA-N n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 CGMMOCAINOCYJN-UHFFFAOYSA-N 0.000 claims 1
- VMKWXXICDHUSCJ-UHFFFAOYSA-N n-[4-[1-(2-methylpropyl)pyrazol-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 VMKWXXICDHUSCJ-UHFFFAOYSA-N 0.000 claims 1
- XDFDTJBORCYWPW-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-(4-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound CC1=CC=NN=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CC(C)(C)C)C1 XDFDTJBORCYWPW-UHFFFAOYSA-N 0.000 claims 1
- FSNHAYQFYVSIPH-UHFFFAOYSA-N n-[4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=C(Cl)C=C(Cl)C=2)C1 FSNHAYQFYVSIPH-UHFFFAOYSA-N 0.000 claims 1
- SDGUKRUVWBNSBZ-UHFFFAOYSA-N n-[4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=C(Cl)C=CC=2)C1 SDGUKRUVWBNSBZ-UHFFFAOYSA-N 0.000 claims 1
- RJMFBKOZLRYVNA-UHFFFAOYSA-N n-[4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCOCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 RJMFBKOZLRYVNA-UHFFFAOYSA-N 0.000 claims 1
- NPVOUGYCIIPRND-UHFFFAOYSA-N n-[4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=C(F)C=CC=2)C1 NPVOUGYCIIPRND-UHFFFAOYSA-N 0.000 claims 1
- KUQUMTFKLDZYBL-UHFFFAOYSA-N n-[4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 KUQUMTFKLDZYBL-UHFFFAOYSA-N 0.000 claims 1
- LGEVKWMQIDPBNB-UHFFFAOYSA-N n-[4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 LGEVKWMQIDPBNB-UHFFFAOYSA-N 0.000 claims 1
- UAKAQUZVKRRALQ-UHFFFAOYSA-N n-[4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC(Cl)=CC=2)C1 UAKAQUZVKRRALQ-UHFFFAOYSA-N 0.000 claims 1
- UHNXYSLZXVKQDW-UHFFFAOYSA-N n-[4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC(F)=CC=2)C1 UHNXYSLZXVKQDW-UHFFFAOYSA-N 0.000 claims 1
- VWHHEZYBJLELQW-UHFFFAOYSA-N n-[4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC(F)=CC=3)=CC=2)CC1 VWHHEZYBJLELQW-UHFFFAOYSA-N 0.000 claims 1
- ZXLHXQKBAPKWGB-UHFFFAOYSA-N n-[4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 ZXLHXQKBAPKWGB-UHFFFAOYSA-N 0.000 claims 1
- KQPQCYIUJRVXIZ-UHFFFAOYSA-N n-[4-[1-(cyclopropylmethyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1CC1CC1 KQPQCYIUJRVXIZ-UHFFFAOYSA-N 0.000 claims 1
- KEDXIFMYQSFKIR-UHFFFAOYSA-N n-[4-[1-[2-(oxan-4-yl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)CC1CCOCC1 KEDXIFMYQSFKIR-UHFFFAOYSA-N 0.000 claims 1
- JOLLWYKRXONOQC-UHFFFAOYSA-N n-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CNCC1C(=O)NC1=CC=CN=N1 JOLLWYKRXONOQC-UHFFFAOYSA-N 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001308 pyruvoyl group Chemical group O=C([*])C(=O)C([H])([H])[H] 0.000 claims 1
- 201000002471 spleen cancer Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645692P | 2012-05-11 | 2012-05-11 | |
| US61/645,692 | 2012-05-11 | ||
| US201261719013P | 2012-10-26 | 2012-10-26 | |
| US61/719,013 | 2012-10-26 | ||
| US201361779756P | 2013-03-13 | 2013-03-13 | |
| US61/779,756 | 2013-03-13 | ||
| PCT/US2013/040481 WO2013170115A1 (en) | 2012-05-11 | 2013-05-10 | Pyridazine and pyridine derivatives as nampt inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015520752A JP2015520752A (ja) | 2015-07-23 |
| JP2015520752A5 true JP2015520752A5 (enExample) | 2016-06-30 |
Family
ID=48539390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511730A Pending JP2015520752A (ja) | 2012-05-11 | 2013-05-10 | Ｎａｍｐｔ阻害薬としてのピリダジンおよびピリジン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20130303509A1 (enExample) |
| EP (1) | EP2847181A1 (enExample) |
| JP (1) | JP2015520752A (enExample) |
| CN (1) | CN104583194A (enExample) |
| AR (1) | AR091023A1 (enExample) |
| CA (1) | CA2873097A1 (enExample) |
| HK (1) | HK1209739A1 (enExample) |
| MX (1) | MX2014013751A (enExample) |
| TW (1) | TW201350478A (enExample) |
| UY (1) | UY34804A (enExample) |
| WO (1) | WO2013170115A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015520752A (ja) * | 2012-05-11 | 2015-07-23 | アッヴィ・インコーポレイテッド | Ｎａｍｐｔ阻害薬としてのピリダジンおよびピリジン誘導体 |
| CN110845616A (zh) | 2014-03-21 | 2020-02-28 | 艾伯维公司 | 抗-egfr抗体及抗体药物偶联物 |
| WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| US10144742B2 (en) | 2014-04-18 | 2018-12-04 | Millennium Pharmaceuticals, Inc. | Quinoxaline compounds and uses thereof |
| EP3157916B1 (en) | 2014-06-19 | 2018-12-12 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| EP3247705B1 (en) | 2015-01-20 | 2019-11-20 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof as nampt inhibitors |
| AU2017273857B2 (en) | 2016-06-01 | 2021-08-19 | Athira Pharma, Inc. | Compounds |
| CN109563167A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| AU2017277422A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
| JP2019521975A (ja) | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体薬物コンジュゲート |
| PL3458479T4 (pl) | 2016-06-08 | 2021-07-26 | Abbvie Inc. | Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek |
| WO2017214339A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| AU2017281907B2 (en) * | 2016-06-23 | 2021-10-21 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
| SG11201903013SA (en) | 2016-10-18 | 2019-05-30 | Seattle Genetics Inc | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
| JP7350313B2 (ja) | 2016-12-16 | 2023-09-26 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 |
| US10954216B2 (en) | 2016-12-27 | 2021-03-23 | Riken | BMP-signal-inhibiting compound |
| WO2018177993A1 (de) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Pyrazole zur bekämpfung von arthropoden |
| US11932694B2 (en) | 2017-04-19 | 2024-03-19 | Bluefin Biomedicine, Inc. | Anti-VTCN1 antibodies and antibody drug conjugates |
| WO2018201087A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| EP3731844A4 (en) | 2017-12-27 | 2021-08-18 | St. Jude Children's Research Hospital, Inc. | PANTOTHENATE KINASES SMALL MOLECULE MODULATORS |
| AU2018397486B2 (en) | 2017-12-27 | 2025-04-10 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
| WO2019149637A1 (en) * | 2018-01-31 | 2019-08-08 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| JP7062792B2 (ja) | 2018-02-13 | 2022-05-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| BR112020023107A2 (pt) | 2018-05-14 | 2021-02-02 | Ariad Pharmaceuticals, Inc. | sais farmacêuticos de derivados de pirimidina e método de tratamento de distúrbios |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| US20210388018A1 (en) * | 2018-10-01 | 2021-12-16 | Cornell University | Methyl and ethyl nicotinate-riboside-5-phosphates, preparation thereof and methods of use thereof |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3936192B1 (en) | 2019-03-06 | 2025-04-09 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
| WO2021007313A1 (en) * | 2019-07-08 | 2021-01-14 | Mayo Foundation For Medical Education And Research | Wnt activators and methods of use |
| TW202206422A (zh) | 2020-04-23 | 2022-02-16 | 美商普雷辛肯公司 | 用於ｃｄ７３調節之化合物及方法及其適應症 |
| TW202210472A (zh) | 2020-06-05 | 2022-03-16 | 美商奇奈特生物製藥公司 | 纖維母細胞生長因子受體激酶之抑制劑 |
| CN114660219A (zh) * | 2020-12-23 | 2022-06-24 | 安徽古特生物科技有限公司 | 一种β-烟酰胺单核苷酸的检测方法 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CN120958025A (zh) | 2022-12-16 | 2025-11-14 | 费恩治疗有限公司 | 针对含cub结构域的蛋白1(cdcp1)的抗体及其用途 |
| CN117285573B (zh) * | 2023-09-26 | 2024-03-26 | 长沙兴嘉生物工程股份有限公司 | 一种β-烟酰胺单核苷酸金属络合物及其制备方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9406144D0 (en) | 1993-03-29 | 1994-05-18 | Zeneca Ltd | Heterocyclic compounds |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| EP1019385B1 (en) | 1995-09-15 | 2004-01-14 | PHARMACIA & UPJOHN COMPANY | Aminoaryl oxazolidinone n-oxides |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| JP2002512633A (ja) | 1997-06-26 | 2002-04-23 | イーライ・リリー・アンド・カンパニー | 抗血栓剤 |
| CA2294240A1 (en) | 1997-06-26 | 1999-01-07 | Trelia Joyce Craft | Antithrombotic agents |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
| AU2001269531A1 (en) | 2000-07-17 | 2002-01-30 | Takeda Chemical Industries Ltd. | Sulfone derivatives, process for their production and use thereof |
| PL367983A1 (en) | 2001-08-07 | 2005-03-21 | Banyu Pharmaceutical Co, Ltd. | Spiro compounds |
| HUP0200849A2 (hu) * | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| PL205531B1 (pl) | 2002-03-13 | 2010-04-30 | Janssen Pharmaceutica Nv | Pochodna karbonyloaminowa, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna |
| EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| GB0319150D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| WO2005030705A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| CA2547080A1 (en) | 2003-12-02 | 2005-07-28 | Vertex Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors and uses thereof |
| PL1700856T3 (pl) * | 2003-12-26 | 2016-05-31 | Kyowa Hakko Kirin Co Ltd | Pochodna tiazolu |
| PL1737850T3 (pl) | 2004-04-19 | 2008-02-29 | Symed Labs Ltd | Nowy sposób wytwarzania linezolidu i związków pokrewnych |
| DE602004020812D1 (de) | 2004-07-20 | 2009-06-04 | Symed Labs Ltd | Neue zwischenprodukte für linezolid und verwandte verbindungen |
| US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| WO2006058338A2 (en) | 2004-11-29 | 2006-06-01 | Janssen Pharmaceutica N.V. | 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor |
| EP1861372A1 (en) * | 2005-02-24 | 2007-12-05 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| US20090253671A1 (en) | 2005-03-04 | 2009-10-08 | Astrazeneca Ab | Tricyclic derivatives of azetidine and pyrrole with antibacterial activity |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| TW200815426A (en) | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
| WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
| AU2007294686B2 (en) * | 2006-09-15 | 2013-10-31 | Equinox Sciences, Llc | Kinase inhibitor compounds |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| CA2672373C (en) * | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| BRPI0807813A2 (pt) | 2007-02-15 | 2014-08-05 | Hoffmann La Roche | 2-amino-oxazolinas como ligantes de taar1 |
| WO2008131259A1 (en) | 2007-04-19 | 2008-10-30 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| WO2009051782A1 (en) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| AU2008317375B2 (en) | 2007-10-26 | 2013-02-28 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| US20090113874A1 (en) | 2007-11-02 | 2009-05-07 | Caterpillar Inc. | System and method for electrically regenerating a particulate filter assembly of a generator set |
| MX2010009372A (es) | 2008-02-26 | 2010-09-22 | Takeda Pharmaceutical | Derivado heterociclico fusionado y su uso. |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| WO2009153197A1 (en) | 2008-06-18 | 2009-12-23 | F. Hoffmann-La Roche Ag | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| CA2748099C (en) | 2008-12-22 | 2017-02-28 | Array Biopharma Inc. | 7-phenoxychroman carboxylic acid derivatives |
| WO2011025799A1 (en) * | 2009-08-26 | 2011-03-03 | Glaxo Group Limited | Cathepsin c inhibitors |
| CA2810049A1 (en) * | 2010-09-03 | 2012-03-08 | Forma Tm, Llc | Guanidine compounds and compositions for the inhibition of nampt |
| EP2832731A4 (en) * | 2012-03-27 | 2015-08-19 | Shionogi & Co | AROMATIC HETEROCYCLIC CHAIN 5-CORE DERIVED DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY |
| AU2013241854B2 (en) * | 2012-03-28 | 2017-11-02 | Intervet International B.V. | Heteroaryl compounds with cyclic bridging unit for use in the treatment helminth infection |
| JP2015520752A (ja) * | 2012-05-11 | 2015-07-23 | アッヴィ・インコーポレイテッド | Ｎａｍｐｔ阻害薬としてのピリダジンおよびピリジン誘導体 |
| US9296723B2 (en) * | 2012-05-11 | 2016-03-29 | Abbvie Inc. | NAMPT inhibitors |
-
2013
- 2013-05-10 JP JP2015511730A patent/JP2015520752A/ja active Pending
- 2013-05-10 US US13/891,354 patent/US20130303509A1/en not_active Abandoned
- 2013-05-10 UY UY0001034804A patent/UY34804A/es not_active Application Discontinuation
- 2013-05-10 AR ARP130101637A patent/AR091023A1/es unknown
- 2013-05-10 US US13/891,357 patent/US8975398B2/en active Active
- 2013-05-10 WO PCT/US2013/040481 patent/WO2013170115A1/en not_active Ceased
- 2013-05-10 CA CA2873097A patent/CA2873097A1/en not_active Abandoned
- 2013-05-10 HK HK15110586.2A patent/HK1209739A1/xx unknown
- 2013-05-10 CN CN201380036867.6A patent/CN104583194A/zh active Pending
- 2013-05-10 EP EP13726339.8A patent/EP2847181A1/en not_active Withdrawn
- 2013-05-10 MX MX2014013751A patent/MX2014013751A/es unknown
- 2013-05-10 TW TW102116746A patent/TW201350478A/zh unknown
-
2015
- 2015-01-23 US US14/603,832 patent/US20150141398A1/en not_active Abandoned
-
2016
- 2016-11-21 US US15/357,383 patent/US20170065575A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520752A5 (enExample) | ||
| RU2014150049A (ru) | Ингибиторы nampt | |
| CA2873097A1 (en) | Pyridazine and pyridine derivatives as nampt inhibitors | |
| RU2006146608A (ru) | ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ | |
| RU2485114C2 (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов | |
| RU2013133800A (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| JP2014511869A5 (enExample) | ||
| JP2016517878A5 (enExample) | ||
| JP2018530591A5 (enExample) | ||
| RU2017144535A (ru) | Мультизамещенные ароматические соединения в качестве ингибиторов тромбина | |
| RU2017139727A (ru) | Гетероциклические ингибиторы erk1 и erk2 и их применение для лечения злокачественного новообразования | |
| IL288243B1 (en) | Heteroaryl-substituted pyridines and methods of use | |
| RU2009149696A (ru) | 5-замещенные индазолы в качестве ингибиторов киназы | |
| JP2009542721A5 (enExample) | ||
| RU2013126657A (ru) | Ингибиторы nampt и rock | |
| JP2005526723A5 (enExample) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| HRP20150082T1 (hr) | Derivati pirazolo piridina kao inhibitori nadph oksidaze | |
| JP2010505832A5 (enExample) | ||
| JP2014526501A5 (enExample) | ||
| JP2012525349A5 (enExample) | ||
| JP2013542265A5 (enExample) | ||
| RU2011115111A (ru) | Замещенные пирролидин-2-карбоксамиды | |
| JP2008525502A5 (enExample) | ||
| RU2011134868A (ru) | N-замещенные насыщенные гетероциклические сульфоновые соединения с активностью агонистов рецептора св2 |